Last reviewed · How we verify
NCT05772611: Car-Te-Cell
Characterization of Immune-response in Autoimmune Encephalitis and Paraneoplastic Neurological Syndromes
trial testing Genetic and immunology tests in Autoimmune Encephalitis in 180 participants. Currently enrolling.
15 February 2024
Quick facts
| Lead sponsor | Hospices Civils de Lyon |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 180 |
| Start date | 1 February 2022 |
| Primary completion | 15 February 2024 |
| Estimated completion | 15 February 2029 |
| Sites | 1 location across France |
Drugs / interventions tested
- Genetic and immunology tests — full drug profile →
Conditions studied
- Autoimmune Encephalitis — all drugs for Autoimmune Encephalitis →
- Paraneoplastic Neurological Syndrome — all drugs for Paraneoplastic Neurological Syndrome →
Sponsor
Hospices Civils de Lyon — full company profile →
Who can join
18 and older, any sex, with Autoimmune Encephalitis or Paraneoplastic Neurological Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Autoimmune encephalitis (AE) and paraneoplastic neurological syndromes (PNS) are rare neuroimmune syndromes with a wide range of clinical presentation but without pathognomonic clinical sign facilitating the diagnosis. A lot of differential diagnoses are possible such as neurodegenerative diseases or viral infections. Although rare the diagnosis of AE or PNS is essential because despite severe neurological symptoms, patients can be cured by appropriate immunotherapy. Autoantibodies highly specific of AE and PNS has been described in the serum and cerebrospinal fluid of the patients and can be used as biomarkers of the disease. Their presence can predict an autoimmune origin and in many cases a good prognosis after immunotherapy. However, if some autoantibodies are now well-characterized and industrial kits have been developed to detect them, in numerous cases of highly suspect AE or PNS no specific autoantibodies are identified leading frequently to an inappropriate treatment. Furthermore, as the mechanisms of AE and PNS is still unknown, treatments are not optimal and in some cases inefficient. There is no prognosis biomarker able to predict the patient's sensitivity to immunotherapy and there are only few clues to know how the immune system can provoke the neuropsychiatric symptoms observed in the patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Medical Applications of Molecular Biotechnologies in the Context of Hashimoto's Thyroiditis.
Trovato M, Valenti A. · · 2023 · cited 1× · PMID 37371008 · DOI 10.3390/diagnostics13122114
Verify or expand the search:
- PubMed search for NCT05772611
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Autoimmune Encephalitis
Currently open trials in the same condition.
- NCT07477015 — Study of Pathogenic Mechanisms and Identification of Novel Autoantibodies in Autoimmune Encephalitis · recruiting
- NCT06753955 — Phase 1 Study of ART5803 Safety and PK After IVIG in Healthy Participants · Phase 1 · active not recruiting
- NCT06575153 — Phase 1 Study of ART5803 in Healthy Participants · Phase 1 · active not recruiting
- NCT06079294 — Impact of Confirmed Autoimmune Encephalitis on Brain Glucose Metabolism · NA · recruiting
- NCT06432803 — Metabolic Imaging for Diagnosis and Prognostication of Autoimmune encephalitiS · active not recruiting
Other Hospices Civils de Lyon trials
Trials by the same sponsor.
- NCT07569536 — Efficacy of the Alpha 2 Agonist Dexmedetomidine for Sympathetic Deactivation in REfractory Septic Shock · Phase 3 · not yet recruiting
- NCT07529314 — Evaluating Interventional Radiology for Cancer Pain Management · NA · not yet recruiting
- NCT07273929 — Comparative Study of the Effectiveness of Three Access Routes for Implanting an Electronic Intracardiac Device · Phase 3 · not yet recruiting
- NCT07474532 — Attitudes and Beliefs Related to Benzodiazepine Deprescribing · not yet recruiting
- NCT07313007 — Assessment of Gut Microbiota-Derived Amino Acid Metabolite Production in Patients With MASLD · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05772611 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospices Civils de Lyon
- Last refreshed: 16 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05772611.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing